303 related articles for article (PubMed ID: 31796521)
1. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
3. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
4. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
Luu K; Chu A; Chang B
J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
[TBL] [Abstract][Full Text] [Related]
5. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
6. Tisotumab Vedotin: First Approval.
Markham A
Drugs; 2021 Dec; 81(18):2141-2147. PubMed ID: 34748188
[TBL] [Abstract][Full Text] [Related]
7. Mitigation and management strategies for ocular events associated with tisotumab vedotin.
Kim SK; Ursell P; Coleman RL; Monk BJ; Vergote I
Gynecol Oncol; 2022 May; 165(2):385-392. PubMed ID: 35277279
[TBL] [Abstract][Full Text] [Related]
8. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
Yonemori K; Kuboki Y; Hasegawa K; Iwata T; Kato H; Takehara K; Hirashima Y; Kato H; Passey C; Buchbjerg JK; Harris JR; Andreassen CM; Nicacio L; Soumaoro I; Fujiwara K
Cancer Sci; 2022 Aug; 113(8):2788-2797. PubMed ID: 35633184
[TBL] [Abstract][Full Text] [Related]
9. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
10. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote I; Van Nieuwenhuysen E; O'Cearbhaill RE; Westermann A; Lorusso D; Ghamande S; Collins DC; Banerjee S; Mathews CA; Gennigens C; Cibula D; Tewari KS; Madsen K; Köse F; Jackson AL; Boere IA; Scambia G; Randall LM; Sadozye A; Baurain JF; Gort E; Zikán M; Denys HG; Ottevanger N; Forget F; Mondrup Andreassen C; Eaton L; Chisamore MJ; Viana Nicacio L; Soumaoro I; Monk BJ
J Clin Oncol; 2023 Dec; 41(36):5536-5549. PubMed ID: 37651655
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
[TBL] [Abstract][Full Text] [Related]
12. Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Chung HC; Ros W; Delord JP; Perets R; Italiano A; Shapira-Frommer R; Manzuk L; Piha-Paul SA; Xu L; Zeigenfuss S; Pruitt SK; Leary A
J Clin Oncol; 2019 Jun; 37(17):1470-1478. PubMed ID: 30943124
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
[TBL] [Abstract][Full Text] [Related]
15. New Drug Treats Cervical Cancer.
Aschenbrenner DS
Am J Nurs; 2022 Jan; 122(1):21. PubMed ID: 34941590
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
Naumann RW; Hollebecque A; Meyer T; Devlin MJ; Oaknin A; Kerger J; López-Picazo JM; Machiels JP; Delord JP; Evans TRJ; Boni V; Calvo E; Topalian SL; Chen T; Soumaoro I; Li B; Gu J; Zwirtes R; Moore KN
J Clin Oncol; 2019 Nov; 37(31):2825-2834. PubMed ID: 31487218
[TBL] [Abstract][Full Text] [Related]
17. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
Xia X; Jiang W; Qi W; Hong B; Zhao W
Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O
Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Santin AD; Deng W; Frumovitz M; Buza N; Bellone S; Huh W; Khleif S; Lankes HA; Ratner ES; O'Cearbhaill RE; Jazaeri AA; Birrer M
Gynecol Oncol; 2020 Apr; 157(1):161-166. PubMed ID: 31924334
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
